FARMINGTON, Utah / May 13, 2024 / Business Wire / PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”) announced today that Evelyn Dilsaver has been appointed to serve as a member of its Board of Directors. “We’re thrilled to have Evelyn join our board,” said Jason Murray, PACS Chairman and CEO. “She has great experience as an accounting and finance professional, not to mention her work on the boards of several other public companies. She’ll bring added perspective and expertise to the board as we work to guide PACS going forward.”
“I’m excited to join the PACS Board and assist the company in continuing its mission to provide quality skilled nursing care. I look forward to great things ahead for the company,” added Ms. Dilsaver.
Ms. Dilsaver also serves on the boards of directors of Tempur Sealy International (NYSE: TPX), HealthEquity, Inc. (Nasdaq: HQY) and QuidelOrtho (Nasdaq: QDEL). Ms. Dilsaver was President and Chief Executive Officer of Charles Schwab Investment Management from July 2004 until September 2007. Prior to that, she held various senior management positions with The Charles Schwab Corporation. Ms. Dilsaver is a certified public accountant and holds a B.S. degree in accounting from California State University-Hayward.
Ms. Dilsaver is an independent director under applicable NYSE and SEC rules. Her appointment now makes the PACS Board of Directors majority independent. Ms. Dilsaver’s committee appointments will be considered at a later date.
About PACS Group
PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. Founded in 2013, PACS Group is one of the largest post-acute platforms in the United States. Its independent subsidiaries operate over 200 post-acute care facilities across nine states serving over 20,000 patients daily.
| Last Trade: | US$36.39 |
| Daily Change: | 0.99 2.80 |
| Daily Volume: | 1,389,699 |
| Market Cap: | US$5.650B |
November 19, 2025 November 06, 2024 November 01, 2024 September 10, 2024 September 09, 2024 | |

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load